QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

TLX

QT48Telix Pharmaceuticals Limited
NASDAQ·Healthcare·Biotechnology·AU
Latest market price
10.09
+0.15+1.51%
OverviewShort InterestFilings
TLXQT48Telix Pharmaceuticals Limited·NASDAQ
OverviewShort InterestFilings
10.09+1.51%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
0.07
Insider Own-
Shs Outstand-
Perf Week6.77%
Market Cap3.40BForward P/E93.57EPS next Y0.11Insider Trans-Shs Float-Perf Month-0.79%
Enterprise Value3.74BPEG3.68EPS next Q0.01Inst Own-Short Float-Perf Quarter17.74%
Income-7479734.00P/S3.96EPS this Y-40.89%Inst Trans-Short Ratio-Perf Half Y20.98%
Sales857.84MP/B7.79EPS next Y160.61%ROA-0.61%Short Interest-Perf YTD34.71%
Book/sh-P/C-EPS next 5Y107.27%ROE-1.72%52W High17.25 -41.51%Perf Year-39.94%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC1.77%52W Low6.28 60.67%Perf 3Y-
Dividend Est.-EV/EBITDA143.94Sales past 3/5Y91.38% 186.94%Gross Margin50.76%Volatility2.02% 2.85%Perf 5Y-
Dividend TTM-EV/Sales4.36EPS Y/Y TTM-21.62%Oper. Margin2.11%ATR (14)0.33Perf 10Y-
Dividend Ex-Date-Quick Ratio1.27Sales Y/Y TTM151.26%Profit Margin-0.89%RSI (14)57.09Recom2.67
Dividend Gr. 3/5Y-Current Ratio1.43EPS Q/Q-SMA205.97%Beta1.00Target Price20.00
Payout0.00%Debt/Eq1.12Sales Q/Q122.40%SMA50-0.87%Rel Volume0.41Prev Close9.94
Employees1,120LT Debt/Eq1.22EarningsAug 20SMA20010.35%Avg Volume190.65KPrice10.09
IPO DateNov 14, 2024Option/ShortYes / YesEPS/Sales Surpr.-135.40% -1.20%Net Debt/EBITDA13.13Volume77,662Change1.51%
Analyst Ratings
DateActionAnalystRatingTarget
Dec-15-25InitiatedRBC CapitalSector Perform$17
Sep-23-25ReiteratedUBSBuy$20
Sep-10-25ReiteratedH.C. Wainwright$23 → $20
Aug-28-25DowngradeJP MorganOverweight → Neutral
Latest News
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue1,299778517
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A566365180
Gross Profit733413336
Selling, General and Administrative Excl. Other350230137
Research and Development24616680
Other Operating Expense68065
Operating Income701754
Interest Expense253614
Unusual Expense
———
Non-Operating Income (Expense)3-13-7
Net Income Before Taxes32-537
Income Taxes1024
Consolidated Net Income26-733
Net Income From Continuing Operations37-733
Net Income26-733
EPS (Recurring)0.08-0.020.10
EPS (Basic, Before Extraordinaries)0.08-0.020.10
EPS (Diluted)0.07-0.020.09
EBITDA1065265
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
144.14——
Price To Sales Ratio2.633.25—
Gross Margin56.4353.0864.99
Operating Margin5.392.1910.44
Net Margin2.00-0.906.38
Shares Outstanding339338331
Market Capitalization3,4212,532—
Operating Lease Expense
———
Insider Trading Volume
$10.47$9.91$9.34$8.77$8.21● Close Price0.00K249.18K498.37K747.55K996.74KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Behrenbruch ChristianMD & Group CEOApr 29 '26Buy14.8733,435497,17820,742,935May 06 12:00 AM
Behrenbruch ChristianMD & Group CEOApr 28 '26Buy14.4834,500499,56020,709,500May 06 12:00 AM
Smith Darren CharltonGroup Chief Financial OfficerMar 29 '26Option Exercise0.002,222011,921Apr 01 12:00 AM
BRANDT RICHARD PAULdirector, 10 percent owner:Sep 11 '07Option Exercise4.035,00020,1265,160Sep 14 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR